Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatl ...

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Aquiline Drones Embarks on Nationwide Campaign ? Using Disruptive Technologies: Drones and AI cameras to Fight Unsightly Graffiti. Unsightly graffiti is a menace to communities and metropolises, ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...